Life cycle analysis of solvent reduction in pharmaceutical synthesis using continuous adsorption for palladium removal

Slater, C. Stewart; Savelski, Mariano J.; Ruiz-Felix, Marie Nydia

doi:10.1080/10934529.2013.815080

Cited by 14 publications

(6 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most notably, there is a large use of solvents during the production of the NPs, in particular in the PS, where solvent inputs range from about 15 (for PbSe NPs) to 1800 (for CdS NPs) kg/kg NP. The high solvent use is in the same order of magnitude as the solvent use for pharmaceutical production, which can typically range from 25 to more than 100 kg/kg active pharmaceutical ingredient . The PWCs also constitute large inputs in the NP production unit processes in the PS, ranging from about 60 to 800 kg/kg NPs.…”

Section: Resultsmentioning

confidence: 99%

“…The high solvent use is in the same order of magnitude as the solvent use for pharmaceutical production, which can typically range from 25 to more than 100 kg/kg active pharmaceutical ingredient. 63 The PWCs also constitute large inputs in the NP production unit processes in the PS, ranging from about 60 to 800 kg/kg NPs. In the OS, less solvent is required due to a 95% solvent recycling factor.…”

Section: ■ Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prospective Life-Cycle Modeling of Quantum Dot Nanoparticles for Use in Photon Upconversion Devices

Wickerts

Arvidsson

Sandén

et al. 2021

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

Quantum dot nanoparticles (NPs) can be used in several applications, for example, photon upconversion devices that increase the electricity output of solar modules. In order to facilitate life cycle assessment (LCA) studies of such applications, this study provides ready-to-use LCA unit process data for four NPs suitable for photon upconversion applications: cadmium selenide, cadmium sulfide, lead selenide, and lead sulfide. The data is provided for two prospective scenarios: one optimistic and one pessimistic. An impact assessment is conducted in order to assess the NPs' climate change performance, where solvent-related processes such as steam production for recycling and hazardous waste treatment are shown to be hotspots. To show the applicability of the data, a prospective assessment of a solar module with an upconversion layer is conducted to investigate whether it is preferable from a climate perspective to install more solar modules or equip existing ones with upconversion devices, leading to more electricity produced in both cases. The assessment shows that solar modules need to become 0.05−2 percentage points more efficient per gram of NPs applied, depending on the scenario, in order for the upconversion layer to be preferable.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: ■ Methodsmentioning

confidence: 99%

Prospective Life-Cycle Modeling of Quantum Dot Nanoparticles for Use in Photon Upconversion Devices

Wickerts

Arvidsson

Sandén

et al. 2021

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

show abstract

“…Many of the pharmaceutical companies studied are engaging with these principles and other solutions unique to the pharmaceutical industry and drug manufacturing process. The emission reduction potential of green chemistry principles, streamlined batch production, and optimizing pharmaceutical packaging have been demonstrated through several life cycle assessments published in the literature [ 45 , 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies

Booth

Jager

Faulkner

et al. 2023

IJERPH

View full text Add to dashboard Cite

The pharmaceutical industry produces a large proportion of health system greenhouse gas (GHG) emissions, contributing to climate change. This urgently needs to be addressed. We aimed to examine pharmaceutical company climate change targets, GHG emissions, and strategies to reduce them. We performed content analysis of the 20 largest pharmaceutical companies’ publicly available 2020/2021 reports, focusing on extracting information on their reported climate change targets, GHG emissions (and whether companies had demonstrated any reduction in emissions over their reporting period), and strategies being implemented to reduce company emissions and meet their targets. Nineteen companies have committed to reducing GHG emissions, ten to carbon neutrality and eight to net zero emissions between 2025 and 2050. Companies showed largely favorable reductions in scope 1 (in-house) and scope 2 (purchased energy), with variable results in scope 3 (supply chain) emissions. Strategies to reduce emissions included optimizing manufacturing and distribution, and responsible sourcing of energy, water, and raw materials. Pharmaceutical companies are setting climate change targets and reporting reduced emissions via a range of strategies. This varies, with scope to track actions and accountability to targets, improve consistency of reporting, especially of scope 3 emissions, and collaborate on novel solutions. There is need for further mixed methods research on progress with achieving reported climate change targets, as well as implementation of strategies to reduce emissions within the pharmaceutical industry.

show abstract

“…The qualitative comparison of results in Table 2 are as follows; in the raw material extraction and processing phase, the use of chemicals and solvents, the use of fossil energy and intensive water consumption are examples of issues for the TPC, and a decreased total demand of resources can be expected for the CPC (Slater et al, 2013). In the social dimension, it is likely to encounter issues with work conditions for the TPC, and no change can be expected for the CPC.…”

Section: Qualitative Sustainability Performance Comparisonmentioning

confidence: 99%

Decision Support for Re-Designed Medicinal Products - Assessing Consequences of a Customizable Product Design on the Value Chain from a Sustainability Perspective

Siiskonen

Watz

Malmqvist

et al. 2019

Proc. Int. Conf. Eng. Des.

View full text Add to dashboard Cite

Despite advances in pharmacological research providing means for individually customized patient attribute treatments, the 'one-size-fits-all' paradigm remains. Customization is associated with cost increases and the value assessment of customized medicinal products shows upon a narrow economic focus. Inspired by value models, emerging in manufacturing industry research, this study suggests a novel methodology encompassing a full sustainability perspective, including the social, economic and ecological dimension, for design decision support for medicinal products. A concept screening matrix is adapted, using sustainability criteria as value indicators. The focus is to create value for the whole pharmaceutical value chain whilst keeping the core purpose of medicinal products, i.e. to bring societal benefits. An illustrative case study presents an application of the methodology on a commercial product for curing hypertension. The traditional product design for hypertension treatment is compared to a customized product design. Results indicate that a customized product design is preferable if value is to be created from a social or/and an ecological sustainability perspective.

show abstract

Life cycle analysis of solvent reduction in pharmaceutical synthesis using continuous adsorption for palladium removal

Cited by 14 publications

References 13 publications

Prospective Life-Cycle Modeling of Quantum Dot Nanoparticles for Use in Photon Upconversion Devices

Prospective Life-Cycle Modeling of Quantum Dot Nanoparticles for Use in Photon Upconversion Devices

Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies

Decision Support for Re-Designed Medicinal Products - Assessing Consequences of a Customizable Product Design on the Value Chain from a Sustainability Perspective

Contact Info

Product

Resources

About